#USA #Princeton #Kenox Pharmaceuticals #Lactiga US #mucosal therapy

Kenox Pharmaceuticals and Lactiga US Join Forces

In a significant move toward advancing healthcare solutions, Kenox Pharmaceuticals Inc. and Lactiga US, Inc. have announced their strategic collaboration aimed at developing innovative mucosal-targeted therapies for immunodeficient patients. This partnership was catalyzed by a substantial multi-million-dollar STTR grant awarded to Lactiga by the National Institute of Allergy and Infectious Diseases (NIAID), part of the esteemed National Institutes of Health (NIH).

The collaboration between the two companies seeks to leverage Kenox’s rich expertise in the development and manufacturing of nasal and inhaled pharmaceutical products. This initiative is primarily focused on expediting the preclinical development of cutting-edge therapies designed to enhance mucosal immunity, particularly for individuals whose immune systems are compromised.

Sitaram Velaga, President and CEO of Kenox, expressed great enthusiasm about the partnership, emphasizing its potential to deliver life-altering therapies for those in need. He stated, “We are thrilled to partner with Lactiga and contribute to the development of these potentially life-changing therapies. This collaboration, combined with the prestigious NIH grant, underscores the immense potential of this innovative approach to address the unmet needs of immunodeficient patients.”

Commenting on the collaboration, Rikin Mehta, CEO and Co-founder of Lactiga, highlighted the long-standing need for a nasal Secretory IgA (sIgA) spray to help mitigate recurrent respiratory infections in vulnerable populations. “Immunologists have long sought a nasal sIgA spray to reduce recurrent respiratory infections, especially in compromised individuals — a major unmet medical need costing the healthcare system billions of dollars. Through our partnership with Kenox, we are making a first-in-class intranasal sIgA therapy a reality,” he remarked.

This strategic alliance marks a groundbreaking leap towards the development of novel nasal immunotherapies, showcasing the potential to significantly improve the quality of life for individuals with immunodeficiency.

About Kenox Pharmaceuticals Inc.

Founded in 2018 and located in the greater Princeton area of New Jersey, Kenox specializes in developing pharmaceutical aerosol products, which include a variety of inhalers and sprays for both small and biologic molecules. As a contract development organization (CDO), Kenox offers extensive capabilities in formulation design, compounding, fill-finish, and rigorous testing in accordance with compendial monographs.

About Lactiga US, Inc.

Lactiga is a pioneering biotechnology company focused on the development of innovative mucosal antibodies derived from human breastmilk. With a mission to enhance the lives of vulnerable populations, Lactiga specializes in developing sIgA-based therapies that utilize proprietary technologies to create targeted interventions for infectious and inflammatory diseases.

As both companies embark on this collaborative journey, the healthcare sector watches with anticipation the impact these innovative therapies could have on millions of patients worldwide. This partnership not only exemplifies the spirit of innovation and teamwork but also emphasizes the ongoing commitment of both organizations to address significant healthcare challenges through scientific progress.